Foam type hair growth liquid and preparation method thereof

Abstract

The present invention discloses a foam-type hair growth liquid and a preparation method thereof. The foam-type hair growth liquid comprises the following components by mass percentage: 10% to 55% of a surfactant, 0.1% to 1% of an oily substance, 1% to 50% of a cosolvent, 0.05% to 1% of an antibacterial agent, 0.1% to 12% of an active drug, and 30% to 80% of water. The preparation method of the foam-type hair growth liquid comprises the following steps: (1) uniformly mixing the surfactant, the oily substance, the cosolvent and the antibacterial agent, then adding the active drug, heating to fully dissolve it, and obtaining an oil phase containing the drug; (2) dripping the oil phase containing the drug into the water phase to obtain the foam-type hair growth liquid. The present invention prepares a nano-emulsion foam-type hair growth liquid by the above method. The preparation method is simple and the quality is controllable. The prepared nano-emulsion foam-type hair growth liquid can promote the skin penetration of the drug, achieve a better drug treatment effect, and have less toxic and side effects.

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical preparations, and in particular to a foam-type hair growth liquid and a preparation method thereof. Background Art

[0002] Seborrheic alopecia is an androgen-dependent hereditary hair loss disease, the onset of which may be related to endocrine dysfunction, genetics, fungal infection, inflammation and other factors. At present, the research on seborrheic alopecia has been carried out to the molecular level, new therapeutic drugs are constantly emerging, and there is a trend of combining traditional Chinese and Western medicine. At present, there are two main drugs commonly used in clinical treatment of hair loss, finasteride and minoxidil.

[0003] Finasteride is a type II 5α-reductase selective inhibitor that can reduce the conversion of testosterone into dihydrotestosterone, which has stronger receptor binding affinity, thereby weakening the effect of androgens on hair loss. Minoxidil is a non-specific drug for treating hair loss and is a first-line topical drug approved by the FDA for the treatment of seborrheic alopecia. The mechanism of minoxidil in preventing and treating hair loss is: opening potassium ion channels, inhibiting calcium ion influx, reducing the inhibition of epidermal growth factor on hair growth, promoting the proliferation and differentiation of hair follicle epithelial cells, upregulating vascular endothelial growth factor and improving local blood supply.

[0004] At present, most of the finasteride preparations on the market are oral solid preparations, which need to be taken continuously for more than one year to be effective. Moreover, if used in pregnant women, it may cause malformation of the external genitalia of male fetuses and sexual side effects. In addition, long-term oral finasteride may also cause increased body hair, breast development, decreased sexual function, increased cholesterol levels, and emotional disorders. Minoxidil is mostly available in the form of topical liniments or gels on the market, which achieve the purpose of treating hair loss by dilating blood vessels. However, when minoxidil liniment is used, the liquid has strong fluidity and is easy to spray on the face. If it is not cleaned in time, it is easy to cause hirsutism; while minoxidil gel is affected by the dosage form, its drug concentration is far less than other dosage forms, and the therapeutic effect is limited. In order to further improve the therapeutic effect, finasteride and minoxidil are used in combination to prepare topical products, but most of these combined products have no actual synergistic effect. For example, CN103596550A discloses a topical composition for preventing hair loss and promoting hair growth, that is, a topical composition comprising a 5α-reductase inhibitor and minoxidil, for preventing hair loss and promoting hair growth. Since the side effects of 5α-reductase inhibitors are large, the content of 5α-reductase inhibitors in the topical dosage form is reduced. Although the efficacy is improved compared with the application of a single 5α-reductase inhibitor or minoxidil, there are still problems such as a long course of treatment. CN105658223A discloses a composition for reducing hair loss and / or increasing hair regeneration, comprising minoxidil, finasteride and prostaglandin analogs, and a topically administrable spray is prepared for reducing hair loss and increasing hair regeneration in human subjects, but no obvious synergistic effect is achieved.

[0005] In addition, resveratrol is a polyphenolic phytoalexin with antioxidant, anti-inflammatory and anti-apoptotic effects. Recent experiments have verified that resveratrol has the effect of promoting hair growth and prolonging the growth phase of hair follicles, mainly manifested in accelerating the entry into the early growth phase and delaying the progression of the regression phase (Hair Growth-Promoting Effect of Resveratrol in Mice, Human Hair Follicles and Dermal Papilla Cells). Even low concentrations can mediate the proliferation of dermal papilla cells and protect them from oxidative stress. Resveratrol is expected to become a potential drug for the prevention and treatment of hair loss. Glucocorticoids, such as dexamethasone, are also one of the most commonly used, reliable and effective methods for the treatment of alopecia areata. The methods of administration include topical application, local injection and systemic administration. Its mechanism of action is mainly related to anti-inflammatory and immunosuppression.

[0006] Since the current pharmaceutical preparations for treating hair loss have significant side effects and poor effects, there is an urgent need to provide a hair growth liquid with good efficacy and few side effects. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a foam-type hair growth liquid and a preparation method thereof. Finasteride, minoxidil, resveratrol or dexamethasone with different mechanisms are used in combination and prepared into a nanoemulsion foam-type hair growth liquid, with a simple process and controllable quality. The prepared foam spray does not flow, the foam is stable, and can be in full contact with the lesion for a long time, thereby promoting the deep penetration of the drug into the scalp, prolonging the retention time of the drug in the body, and having better drug efficacy. The production of the foam film can reduce chemical and physical stimulation to the administration site, and has smaller toxic and side effects.

[0008] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0009] The first aspect of the present invention provides a foam-type hair growth liquid, which comprises the following components by mass percentage: 10% to 55% of a surfactant, 0.1% to 1% of an oily substance, 1% to 50% of a solubilizing agent, 0.05% to 1% of an antibacterial agent, 0.1% to 12% of an active drug, and 30% to 80% of water, wherein the oily substance is fat, and the active drug is selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone.

[0010] Furthermore, when the foam type hair growth liquid contains finasteride, the mass proportion of the finasteride in the foam type hair growth liquid is 0.1% to 1%; when the foam type hair growth liquid contains minoxidil, the mass proportion of the minoxidil in the foam type hair growth liquid is 1% to 5%; when the foam type hair growth liquid contains resveratrol, the mass proportion of the resveratrol in the foam type hair growth liquid is 1% to 5%; when the foam type hair growth liquid contains dexamethasone, the mass proportion of the dexamethasone in the foam type hair growth liquid is 0.1% to 1%.

[0011] Furthermore, the surfactant is caprylic / capric macrogol glyceride and / or polyglycerol-3 oleate.

[0012] Furthermore, the cosolvent is propylene glycol. Studies have shown that the introduction of propylene glycol can improve the solubility of minoxidil.

[0013] Furthermore, the antibacterial agent is phenoxyethanol and / or methyl paraben.

[0014] Furthermore, the foam-type hair growth liquid comprises the following components, measured by mass percentage: 10% to 40% of caprylic capric macrogol glyceride, 0.1% to 15% of polyglycerol-3 oleate, 0.1% to 1% of medium-chain triglycerides, 1% to 50% of propylene glycol, 0.01% to 1% of phenoxyethanol, 0.01% to 1% of methyl paraben, 0.1% to 12% of active drugs, and 30% to 80% of water, wherein the active drugs are selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone.

[0015] Furthermore, the foam-type hair growth liquid further comprises 0.01% to 1% of essence in terms of mass percentage.

[0016] Furthermore, the foam-type hair growth liquid is composed of the following components in percentage by mass: 24% of caprylic capric macrogol glyceride, 2.7% of polyglycerol-3 oleate, 0.5% of medium-chain triglycerides, 4% of propylene glycol, 0.5% of phenoxyethanol, 0.1% of methyl paraben, 0.1% to 12% of active drugs, 0.1% of flavor, and the rest is water; the active drugs are selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone.

[0017] Furthermore, the foam-type hair growth liquid preferably contains 0.1% to 5% of active drugs by mass percentage.

[0018] Furthermore, the active drug comprises minoxidil, and the mass proportion of minoxidil in the foam type hair growth liquid is 2%.

[0019] Furthermore, the active drug also contains one or more of finasteride, resveratrol, and dexamethasone; the mass proportion of finasteride in the foamy hair growth liquid is 0.25%, the mass proportion of resveratrol in the foamy hair growth liquid is 1.2%, and the mass proportion of dexamethasone in the foamy hair growth liquid is 0.1%.

[0020] The second aspect of the present invention provides a method for preparing the foam-type hair growth liquid according to the first aspect, comprising the following steps:

[0021] (1) The surfactant, oily substance, cosolvent and antibacterial agent are mixed uniformly, and then the active drug is added and heated to fully dissolve the active drug to obtain an oil phase containing the drug;

[0022] (2) Adding the oil phase containing the drug dropwise into the water phase to obtain the foam-type hair growth liquid.

[0023] Furthermore, in step (1), the mixing temperature is 40 to 70°C.

[0024] Furthermore, in step (1), the heating temperature is 40 to 70°C.

[0025] Furthermore, in step (2), the aqueous phase is water or an aqueous solution formed by other water-soluble additives and water.

[0026] Furthermore, in step (2), the oil phase containing the drug is added dropwise to the water phase at a uniform rate under stirring.

[0027] Furthermore, when the foamy hair growth liquid contains essence, the oil phase containing the drug is added dropwise to the water phase, and then the essence is added.

[0028] Furthermore, the foam-type hair growth liquid is a nanoemulsion.

[0029] Nanoemulsion is a transparent or translucent system with a particle size of 10 to 100 nm, low viscosity, isotropic thermodynamics and kinetic stability, formed by water phase, oil phase, surfactant and co-surfactant in appropriate proportions. Nanoemulsion can increase the solubility of poorly soluble drugs, and at the same time improve the structure and permeability of the stratum corneum of the skin, which helps to promote the transdermal absorption of drugs and enhance the efficacy of drugs. Therefore, while ensuring the efficacy, the concentration of drugs in hair growth fluid can be reduced, thereby reducing the side effects of drugs. The prepared nanoemulsion foam is passed through a specific drug delivery device, and air is introduced to generate a large amount of foam. The generation of the foam film will reduce the chemical and physical stimulation to the drug delivery site, and the practicality and compliance are better.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] 1. The present invention provides a foam-type hair growth liquid containing one or more drugs with different mechanisms that can promote hair growth or inhibit hair loss. This type of nanoemulsion can increase the solubility of poorly soluble drugs, while improving the permeability of drugs in the stratum corneum of the skin, and promoting the transdermal absorption of drugs; in addition, the nanoemulsion prepared by the present invention can be introduced into air through a specific drug delivery device to generate a large amount of foam dosage form. The generation of foam film will reduce chemical and physical stimulation to the drug delivery site, and the practicality and compliance are better.

[0032] 2. Compared with other dosage forms, the ejection of the nanoemulsion foam-type hair growth liquid provided by the present invention does not flow, the foam is stable, and can be in full contact with the lesion for a long time, thereby promoting the deep penetration of the drug into the scalp, prolonging the retention time of the drug in the body, having better efficacy and less toxic and side effects.

[0033] 3. The present invention also provides a method for preparing the above-mentioned nanoemulsion foam-type hair growth liquid, which is simple, has controllable quality, is low in cost, and is suitable for industrial mass production. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1From left to right are the appearance pictures of the hair growth liquid of Examples 1-8;

[0035] Figure 2 This is a picture of the appearance of the foam after the hair growth liquid of Example 1-8 is squeezed out by a power pump;

[0036] Figure 3 This is a diagram showing the effects of foamy hair growth liquid and commercially available minoxidil tincture on the growth of hair on the back of mice;

[0037] Figure 4 The results are statistical analysis of the effects of foamy hair growth liquid and commercially available minoxidil tincture on hair growth in mice. DETAILED DESCRIPTION

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0039] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0040] Example 1

[0041] This embodiment relates to the preparation of a foam-type hair-growth liquid. The drug component in the foam-type hair-growth liquid is minoxidil, which accounts for 2% by weight in the foam-type hair-growth liquid.

[0042] The specific preparation process is as follows:

[0043] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methylparaben, respectively, and heat and stir at 60° C. for 5 min to mix, then add 0.2 g of minoxidil to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0044] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.61 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0045] Example 2

[0046] This embodiment relates to the preparation of a foam-type hair-growth liquid. The drug component in the foam-type hair-growth liquid is finasteride, and its mass proportion in the foam-type hair-growth liquid is 0.25%.

[0047] The specific preparation process is as follows:

[0048] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben respectively, heat and stir at 60° C. for 5 min to mix, then add 0.025 g of finasteride to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0049] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.785 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0050] Example 3

[0051] This embodiment relates to the preparation of a foam-type hair-growth liquid. The drug component in the foam-type hair-growth liquid is resveratrol, which accounts for 1.2% by weight in the foam-type hair-growth liquid.

[0052] The specific preparation process is as follows:

[0053] (1) Weighing 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben respectively, heating and stirring at 60° C. for 5 min to mix, then adding 0.12 g of resveratrol to the mixture, heating and stirring at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0054] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.69 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0055] Example 4

[0056] The present embodiment relates to the preparation of a foam-type hair growth liquid, wherein the drug ingredients in the foam-type hair growth liquid are finasteride and minoxidil, wherein the mass proportion of finasteride in the foam-type hair growth liquid is 0.25%, and the mass proportion of minoxidil in the foam-type hair growth liquid is 2%.

[0057] The specific preparation process is as follows:

[0058] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben respectively, heat and stir at 60° C. for 5 min to mix, then add 0.025 g of finasteride and 0.2 g of minoxidil to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0059] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.585 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0060] Example 5

[0061] The present embodiment relates to the preparation of a foam-type hair growth liquid, wherein the drug components in the foam-type hair growth liquid are minoxidil and resveratrol, wherein the mass proportion of minoxidil in the foam-type hair growth liquid is 2%, and the mass proportion of resveratrol in the foam-type hair growth liquid is 1.2%.

[0062] The specific preparation process is as follows:

[0063] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methylparaben, respectively, and heat and stir at 60° C. for 5 min to mix, then add 0.2 g of minoxidil and 0.12 g of resveratrol to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve them, to obtain an oil phase containing the drug;

[0064] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.49 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0065] Example 6

[0066] The present embodiment relates to the preparation of a foam-type hair growth liquid, wherein the drug ingredients in the foam-type hair growth liquid are finasteride and resveratrol, wherein the mass proportion of finasteride in the foam-type hair growth liquid is 0.25%, and the mass proportion of resveratrol in the foam-type hair growth liquid is 1.2%.

[0067] The specific preparation process is as follows:

[0068] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben, respectively, and heat and stir at 60° C. for 5 min to mix, then add 0.025 g of finasteride and 0.12 g of resveratrol to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0069] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.665 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0070] Example 7

[0071] The present embodiment relates to the preparation of a foam-type hair growth liquid, wherein the drug ingredients in the foam-type hair growth liquid are minoxidil, finasteride, and resveratrol, wherein the mass proportion of minoxidil in the foam-type hair growth liquid is 2%, the mass proportion of finasteride in the foam-type hair growth liquid is 0.25%, and the mass proportion of resveratrol in the foam-type hair growth liquid is 1.2%.

[0072] The specific preparation process is as follows:

[0073] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben, heat and stir at 60° C. for 5 min to mix, then add 0.2 g of minoxidil, 0.025 g of finasteride and 0.12 g of resveratrol to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0074] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.465 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0075] Example 8

[0076] The present embodiment relates to the preparation of a foam-type hair growth liquid, wherein the drug ingredients in the foam-type hair growth liquid are minoxidil, dexamethasone, and resveratrol, wherein the mass proportion of minoxidil in the foam-type hair growth liquid is 2%, the mass proportion of dexamethasone in the foam-type hair growth liquid is 0.1%, and the mass proportion of resveratrol in the foam-type hair growth liquid is 1.2%.

[0077] The specific preparation process is as follows:

[0078] (1) Weigh 2.4 g of caprylic capric macrogol glyceride, 0.27 g of polyglycerol-3 oleate, 0.05 g of medium chain triglyceride, 0.4 g of propylene glycol, 0.05 g of phenoxyethanol and 0.01 g of methyl paraben, heat and stir at 60° C. for 5 min to mix, then add 0.2 g of minoxidil, 0.01 g of dexamethasone and 0.12 g of resveratrol to the mixture, heat and stir at the same temperature for 0.5 h to fully dissolve it, to obtain an oil phase containing the drug;

[0079] (2) Under stirring conditions at room temperature, the drug-containing oil phase prepared in step (1) is added dropwise to 6.48 g of water, and 0.01 g of essence is added and mixed evenly to obtain a foamy hair growth liquid.

[0080] Performance testing and application

[0081] 1. Nanoemulsion particle size test

[0082] The foam type hair growth liquid prepared in the above-mentioned embodiments 1 to 8 is as follows Figure 1 As shown, each hair growth liquid is clear and transparent. Take an appropriate amount of the foam type hair growth liquid prepared in Examples 1 to 8 above, and use a nanoparticle size and Zeta potential analyzer to measure the particle size and particle size distribution index (PDI). The test is repeated 3 times and the average value is taken. The test results are shown in Table 1 below:

[0083] Table 1 Particle size and PDI of foamy hair growth liquid prepared in different embodiments

[0084] sample Average particle size ± SD / nm PDI Example 1 9.55±0.501 0.166±0.015 Example 2 11.39±0.182 0.174±0.033 Example 3 42.21±1.025 0.427±0.043 Example 4 11.81±0.051 0.134±0.041 Example 5 63.72±1.12 0.452±0.006 Example 6 48.61±0.390 0.402±0.01 Example 7 77.99±0.710 0.318±0.011 Example 8 73.38±0.764 0.314±0.002

[0085] It can be seen from the above table that the particle size of the foam-type hair growth liquid prepared by the method of the present invention is less than 100 nm, forming a nanoemulsion.

[0086] 2. Foam morphology evaluation

[0087] The same amount of the foam-type hair growth liquid prepared in Examples 1 to 8 was taken and squeezed out in a culture dish using a power pump to form foam. The foam morphology of each sample was as follows: Figure 2 As shown, the spray of each sample does not flow, and the foam is fine, uniform and stable; the foam duration is further recorded, measured 3 times, and the average value is taken. The test results are shown in Table 2 below:

[0088] Table 2 Foam duration of foam type hair growth liquid prepared in different embodiments

[0089] Example Foam duration ± SD / min 1 7.14±1.40 2 7.81±1.12 3 14.10±1.27 4 7.50±1.08 5 14.80±0.65 6 14.22±4.79 7 7.44±1.75 8 11.30±1.94

[0090] It can be seen from the above table that the foamy hair growth liquid prepared in the above embodiments can squeeze out foam for at least 5 minutes, and can even last for more than 15 minutes.

[0091] 3. Pharmacodynamic evaluation

[0092] Four male C57BL / 6 mice were selected and anesthetized with ether. Their backs were shaved and then depilated with a depilatory cream. An androgenic alopecia mouse model was established by daily topical application of testosterone ethanol solution. The mice were randomly divided into four groups, namely a blank control group, a positive control group, and an experimental group. The positive control group was smeared with a commercially available 5% minoxidil tincture, and the experimental group was smeared with the foam-type hair growth solution prepared in Example 4 and Example 5. The drug was administered once a day starting from the first day after depilation for two consecutive weeks. The hair growth on the back of the mice was recorded daily. The results are shown in the figure. Figure 3 shown.

[0093] from Figure 3 It can be seen that the back skin of mice treated with foam hair growth solution turned gray on the 14th day compared with the back skin of mice in the control group, and the hair grew more and denser on the 21st day. Compared with mice treated with commercially available 5% minoxidil tincture, the hair growth period of mice treated with foam hair growth solution was slower, but the appearance of the back of mice on the 21st day (see Figure 3 ) and measuring hair length (see Figure 4 ) It can be seen that the hair growth effect of the foam type hair growth liquid and the commercially available 5% minoxidil tincture is comparable. This shows that the foam type hair growth liquid can promote hair growth in mice. Compared with 5% minoxidil, the 2% minoxidil compound foam type nanoemulsion hair growth liquid has fewer side effects and a lower incidence of adverse events.

[0094] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A foam type hair growth liquid, It is characterized in that The foam-type hair growth liquid comprises the following components by mass percentage: 10% to 40% of caprylic capric acid macrogol glyceride, 0.1% to 15% of polyglycerol-3 oleate, 0.1% to 1% of medium-chain triglycerides, 1% to 50% of propylene glycol, 0.01% to 1% of phenoxyethanol, 0.01% to 1% of methyl paraben, 0.1% to 12% of active drugs, and 30% to 80% of water, wherein the active drugs are selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone; the foam-type hair growth liquid is a nanoemulsion.

2. A foam type hair growth liquid according to claim 1, It is characterized in that Calculated by mass percentage, the foamy hair growth liquid also includes 0.01% to 1% of essence.

3. The foam type hair growth liquid according to claim 2, It is characterized in that The foam-type hair growth liquid is composed of the following components by mass percentage: 24% of caprylic capric macrogol glyceride, 2.7% of polyglycerol-3 oleate, 0.5% of medium-chain triglycerides, 4% of propylene glycol, 0.5% of phenoxyethanol, 0.1% of methyl paraben, 0.1% to 12% of active drugs, 0.1% of flavor, and the rest is water; the active drugs are selected from one or more of finasteride, minoxidil, resveratrol, and dexamethasone.

4. A foam type hair growth liquid according to claim 3, It is characterized in that The active drug comprises minoxidil, and the mass proportion of the minoxidil in the foam type hair growth liquid is 2%.

5. A foam type hair growth liquid according to claim 4, It is characterized in that The active drug also contains one or more of finasteride, resveratrol, and dexamethasone; the mass proportion of finasteride in the foam type hair growth liquid is 0.25%, the mass proportion of resveratrol in the foam type hair growth liquid is 1.2%, and the mass proportion of dexamethasone in the foam type hair growth liquid is 0.1%.

6. A method for preparing the foam type hair growth liquid according to any one of claims 1 to 5, It is characterized in that The following steps are involved: (1) A surfactant, an oily substance, a cosolvent and an antibacterial agent are mixed uniformly, and then an active drug is added, and heated to fully dissolve the active drug to obtain an oil phase containing the drug; the surfactant is caprylic acid capric acid macrogol glyceride and polyglycerol-3 oleate, the oily substance is a medium chain triglyceride, the cosolvent is propylene glycol, and the antibacterial agent is phenoxyethanol and methyl paraben; (2) Adding the oil phase containing the drug dropwise into the water phase to obtain the foamy hair growth liquid.

7. The preparation method according to claim 6, It is characterized in that In step (1), the heating temperature is 40-70°C.

Images